Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
  • C07D471/14—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
  • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/08—Vasodilators for multiple indications
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives

Definitions

• This invention relates to the use of imidazo [1,5-a] -pyrido [3,2-e] -pyrazinos of the formula 1 as active ingredients for the treatment of erectile dysfunction (impotence), processes for their preparation and pharmaceutical preparations contain these connections.
• This invention further relates to the use of imidazo [1,5-a] -pyrido [3,2-e] -pyrazinones of the formula 1 as active ingredients for the treatment of heart failure, pulmonary hypertension and vascular diseases which are associated with reduced blood flow and pharmaceutical preparations that contain these compounds.
• PDE enzymes cleave cyclic guanosine 3 ' , 5 ' monophosphate (cGMP) or cyclic adenosine 3 ' , 5 ' monophosphate (cAMP), which occur as 'second messengers' in a large number of cells.
• Phosphodiesterase 5 PDE 5
• PDE5 is cGMP-specific and dominates in the tissue of the human corpus cavernosum.
• the inhibition of PDE5 in human cavernous corpus leads to an increase in the intracellular cGMP level induced by NO. This involves relaxation of the smooth muscles of the cavernous body and, as a result, an erection.
• Inhibitors of PDE 5 are therefore suitable as therapeutic agents for the indication of erectile dysfunction. There is above all a need for such new PDE 5 inhibitors which can be used as orally active ingredients.
• imidazo [1, 5-a] -pyrido [3,2-e] -pyrazinones have so far been completely unknown as active ingredients for the treatment of erectile dysfunction.
• Cardiovascular disease is one of the leading causes of death worldwide. In 1998, 30.9% of all deaths in WHO member countries were attributable to cardiovascular diseases, and 13.7% of these were due to coronary heart diseases (The World Health Report 1999). However, cardiovascular diseases not only affect older people, they also appear frequently from the 3rd decade of life. They not only affect the quality of life of the patients, but are also of great economic importance due to direct and indirect costs. In addition to genetic factors, malnutrition and obesity, alcohol and nicotine abuse and a lack of physical activity play a role in the pathogenesis of cardiovascular diseases. A common clinical picture is coronary heart disease, under which the angina pectoris and the heart attack are summarized. Angina pectoris is a multifactorial clinical picture that is caused by atherosclerosis of the coronary arteries.
• Flow-limiting coronary artery stenosis leads to reduced blood flow to the heart muscles in the form of stable or unstable angina pectoris, dumb myocardial ischemia, ischemic heart failure, cardiac arrhythmia or an acute myocardial infarction.
• the heart attack is caused by the occlusion of a coronary artery with a thrombus (blood clot).
• the thrombus mostly gets stuck on a narrowing of the coronary arteries.
• the regions of the heart muscle lying behind are then no longer supplied with blood.
• large or small areas may be affected.
• the basic therapy consists in the elimination of the known risk factors and a medicinal inhibition of platelet aggregation using acetylsalicylic acid or ticlopidine.
• Vascular dilators such as nitrates, beta-blockers or calcium channel blockers are used to treat angina attacks, but these can have undesirable effects such as hypotension, redistribution of blood (steal phenomenon) or cardio-depressive side effects.
• Bypass surgery can be performed in patients with precisely localized coronary stenosis (guideline - coronary heart disease / angina pectoris. Guideline 019/001 of June 22, 1998 of the German Society for Cardiology - cardiovascular research in the working group of the scientific medical associations) .
• Heart failure Another important disease is heart failure. Due to various factors, the pumping capacity of the heart is no longer sufficient to ensure the blood and thus oxygen supply to the body. A distinction is made between three forms of heart failure, right heart, left heart and global heart failure Right heart failure is the right ventricle no longer able to pump the required amount of blood into the pulmonary circulation. But since blood from the circulatory system continues to reach the right heart, because the left ventricle is uninterrupted Continuing to work, the blood accumulates back in the stomach, liver and even in the legs.
• Left heart failure is when the left ventricle is no longer performing properly. In this case, the blood builds up in the lungs. With global heart failure, both ventricles are affected, often as a result of a previous right or left heart failure.
• the primary disease always comes first, e.g. cardiac arrhythmia (and other heart diseases). or hypertension
• medication to strengthen or relieve the heart depending on the cause of the heart weakness
• dehydrating medication diuretics, volume relief
• inhibitors of phosphodiesterase 3 can increase the concentration of cyclic adenosine monophosphate (cAMP) in the myocardium, which increases the contractile force via various cAMP-dependent protein kinases.
• PDE3 inhibitors Amr inon, milrinone
• Amr inon, milrinone are clearly positively inotropic, but long-term use tends to shorten life expectancy.Therefore, these substances may only be used for the treatment of acute stages (duration of use 2-3 weeks) .
• ß-adrenoceptor agonists such as dopamine and dobutamine which have a direct positive inotropic effect, but are only suitable for the treatment of an acute phase of heart failure.
• Angiotensin converting enzyme eg Captop ⁇ l, enalapril
• angiotensin receptor antagonists eg losartan
• selective ⁇ 1-adreno-receptor blockers e.g. prazosin
• organic nitrates are used.
• Heart transplantation is only carried out in absolutely necessary cases. It is the last option if all other measures have failed.
• transplants, including on other organs, have become routine heart transplants are not unpro blemish Puimonal hypertension occurs when the pulmonary artery pressure rises above 25 mm Hg. This subsequently leads to the development of a cor mememonale (enlargement of the right ventricle).
• the therapy consists in reducing the pulmonary pressure and thus relieving the right ventricle of the heart So far, only substances are available that have a non-selective vascular dilatation effect (ACE inhibitors, Ca antagonists dihydropyridines) or are only used experimentally (inhalative nitrogen oxide (NO), epoprostenol (PGI2) or prostacyclin, adenosine and PGE1, medical and surgical Treatment of Advanced Pulmonary Hypertension By Kenneth W. Presberg, Division of Pulmonary and Critical Gare Mediane, Medical College of Wisconsin Thoracic Medical and Surgical Managment, Volume III, Number 2 1996)
• Phosphodiesterases are a family of isoenzymes, could be assigned to the so far 10 different isoenzymes PDE enzymes cleave, by hydrolysis Guanos ⁇ n cyclic-3 ', 5' monophosphate (cGMP) or cyclic Adenos ⁇ n-3 ', 5' monophosphate ( cAMP), which occur as 'second messengers' in a large number of cells.
• Phosphodiesterase 3 PDE 3
• PDE 5 phosphodiesterase 5
• PDE 5 is cGMP-specific
• the invention relates to the use of imidazo [1, 5-a] -pyrido [3,2-e] - pyrazinones of the formula 1 as active ingredients for the treatment of heart failure, pulmonary hypertension and vascular diseases which are associated with reduced blood flow inhibit PDE 3 and PDE 5 at the same time and to a comparable extent.
• PDE 3 The inhibition of PDE 3 in the heart muscles leads to an increase in heart contractility in a manner known per se (positive inotropic effect). Inhibition of PDE 5 leads to vasodilation, especially in the arterial vessels, and thus reduces e.g. vascular resistance in the coronary arteries or pulmonary artery.
• Imidazo [1, 5-a] -pyrido [3,2-e] -pyrazinones have so far been completely unknown as dual inhibitors of PDE 3 and PDE 5.
• European patent 0 400 583 relates to imidazoquinoxalines of the general formula
• R 1 can be NO2 or CF3 and X for various nitrogen-containing ones
• the invention relates to imidazo [1,5-a] pyrido [3,2-e] pyrazinones of the formula 1
• A represents O or NH
• R 1 , R 2 , R 3 may be the same or different and hydrogen, as well
• -Ci 8-alkyl straight-chain or branched-chain, optionally mono- or polysubstituted with -OH, -SH, -NH 2 , -NHd 6 -alkyl,
• Heterocycles with 5 15 ring members and 1 6 heteroatoms which are preferably N, O and S, -mono-, bi- or tncyclic saturated or mono- or polyunsaturated carbocycles with 3 14 ring members, optionally mono- or polysubstituted with -OH, -SH, -NH 2 , -NHCi 6 alkyl,
• the invention also relates to the physiologically acceptable salts of the compounds of formula 1, which can be obtained by neutralizing the bases with inorganic or organic acids or by neutralizing the acids with inorganic or organic bases or by quaternizing tertiary amines to form quaternary ammonium salts
• the invention in the case of compounds of formula 1 with an asymmetric carbon atom, the invention relates to the D-form, the L-form and D, L-mixtures and, in the case of several asymmetric carbon atoms, to the diastereomeric forms
• the invention further relates to a process for the preparation of the compounds according to the invention corresponding to formula 1.
• the compounds of the general formula ⁇ having the meanings of A, R 1 , R 2 and R 3 shown above are prepared by 3-aminopyridines of the formula 2 with identical Meaning of A, R 1 , R 2 and R 3
• a particularly preferred variant in the sense of the production process according to the invention for the preparation of the ureas of the formula 3 consists in the use of alkali cyanates
• a preferred variant in the sense of the production process according to the invention for the preparation of the ureas of the formula 3 consists in the reaction in protic solvents, particularly preferably in acetic acid
• a preferred variant in the sense of the production process according to the invention for the preparation of the ureas of the formula 3 consists in the reaction in the presence of a mineral acid, particularly preferably in the presence of a concentrated mineral acid miscible with the solvent used, such as, for example, in the presence of concentrated hydrochloric acid
• a preferred variant in the sense of the production process according to the invention for the cyclization of the ureas of the formula 3 to form the compounds of the formula ⁇ according to the invention consists in the use of solvents with a boiling point> 80 ° C., particularly preferably of solvents with a boiling point> 100 ° C.
• the compounds of the formula according to the invention and the medicaments which contain the compounds of formula 1 according to the invention can be used both individually and in combination with one another.
• the compounds according to the invention can be used as veterinary therapeutic agents for the prophylaxis and therapy of erectile dysfunction in male mammals.
• the dosage, the application scheme and the galenical formulation of the compound are carried out taking into account species differences and the requirements of veterinary practice.
• the invention further relates to those imidazo [1, 5-a] pyrido [3,2-e] pyrazinones of the formula 1
• A represents O or NH
• R 1 and R 2 may be the same or different and
• -d 5-alkyl straight-chain or branched-chain, optionally mono- or polysubstituted with -OH, -SH, -NH 2 , -NO 2 , -CN, -COOH,
• -F, -Cl, -Br, -I, -O-d e-alkyl, -S-C, e-alkyl can mean and
• Hydrogen as well -C-s-alkyl, straight-chain or branched-chain, optionally mono- or polysubstituted with -OH, -SH, -NH 2 , -NO 2 , -CN, -COOH, -F, -Cl, -Br, -I, -OC 1 6 -alkyl, -S-Ci e-alkyl or phenyl, their use as therapeutic agents for the treatment of heart failure, pulmonary hypertension and vascular diseases associated with a
• the invention also relates to the physiologically acceptable salts of these compounds, which are neutralized by neutralizing the bases with inorganic or organic acids or can be obtained by neutralizing the acids with inorganic or organic bases or by quaternizing tertiary nurses to quaternary ammonium salts
• the invention relates to compounds with an asymmetric carbon atom, the D-form, the L-form and DN mixtures and in the case of several asymmetric carbon atoms, the diastereomeric forms
• the compounds according to the invention can be administered systemically, for example intravenously, intramuscularly, subcutaneously, or orally. Oral application of the compounds according to the invention is particularly preferred.
• the compounds can also be used as solutions parenterally, buccally or sublingually.
• Medicaments which contain one or more of the compounds of formula 1 according to the invention in addition to customary physiologically tolerable carriers and / or diluents or auxiliaries, and also processes for the preparation of these medicaments are also part of this invention.
• the compounds of formula 1 according to the invention mentioned and the medicaments which contain the compounds according to the invention of formula ⁇ mentioned can be used both individually and in combination with one another.
• the compounds of formula 1 mentioned can be used especially for the treatment of the acute phase of heart failure, coronary heart disease and cor mememonale.
• N- [6-methoxy-2- (4-methyl-2-propyl-imidazol-1-yl) pyrid-3-yl] urea crystallizes out. This intermediate is separated, washed with water and dried at 60 ° C.
• compound 1 can be dissolved in 1N hydrochloric acid in a ratio of 10-50 mg per ml. With further dilution with distilled water, the 10 volume% of polyethylene glycol 660-12 hydroxystearate (Solutol® HS 15) are added, in a ratio of 1: 9 a clear solution is obtained which contains 1-5 mg / ml of compound 1 and can be used as a drinking or injection solution
• the compounds according to the invention are strong inhibitors of phosphodiesterase 5. Their therapeutic potential is demonstrated in vitro, for example by increasing the effect of NO on the intracellular cGMP levels in fibroblasts in rats and relaxing human corpus cavernosum
• the PDE 5 actinate is determined in enzyme preparations from human thrombocytes. Human blood was anticoagulated with citrate. By centrifugation at 700 xg for 20 minutes at room temperature, the thrombocyte-rich plasma in the supernatant is separated from the erythrocytes and leukocytes.
• the thrombocytes are lysed by ultrasound and in the PDE 5-assay used
• the phosphodiesterase activity is determined with some modifications according to the method described by Thompson et al (Thompson, WJ, Appleman, MM, Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme Adv Cycl Nucl Res 1979, 10, 69-92)
• the reaction mixtures contain 50 mM T ⁇ s-HCl (pH 7.4), 5 mM MgCl2, the inhibitors in variable concentrations, the enzyme preparation and the further components necessary for the detection of the individual isoenzyme PDE 5 (see below) the addition of the substrate 0.5 ⁇ M [ 3 H] -cGMP (ca 6000 CPM / Test) the reaction is started.
• Test substances are prepared as stock solutions in DMSO.
• the DMSO concentration in the reaction mixture is 1% v / v. At this DMSO concentration, the PDE 5 activity is not affected.
• the samples are incubated at 37 ° C. for 30 minutes.
• the reaction is stopped by heating the test tubes to 110 ° C. for 2 minutes.
• the samples remain in the ice for another 10 minutes.
• 30 ⁇ l of 5 ' nucleotidase (1 mg / ml, from a snake venom suspension from Crotalus adamanteus
• Rat fetal lung fibroblast cells are a suitable medium for investigating the influence of NO on intracellular cGMP levels (Ishn et al 1991). mechanism can be transferred to the smooth vascular muscles in the corpus cavernosum.
• the compounds according to the invention amplify the increase in the intracellular cGMP levels induced by the NO donor S-nitroso-N-acetyl-D, L-penicillamine.
• Compound 1 for example, significantly induces an increase in the cGMP level at a concentration of 0.010 ⁇ mol / l.
• the activity of compound 1 is 10,000 times stronger than that which is achieved by using the non-specific PDE inhibitor 3-isobutyl-1-methylxanthine (IBMX).
• Strips of human corpus cavernosum are precontracted with noradrenaline in an organ bath.
• the relaxing effect is determined depending on the concentration.
• an EC was, for example, 5 o- value 0.35 mol / i determined for the compound 1
• the compounds of the formula mentioned according to the invention are dual inhibitors of phosphodiesterase 3 and phosphodiesterase 5. Their therapeutic potential is demonstrated in vitro, for example by increasing the effect of NO on the intracellular cGMP levels in fibroblasts of the rat Inhibition of phosphodiesterase 3
• the PDE 3 activity is determined in enzyme preparations from human platelets. Human blood was anticoagulated with citrate. The platelet-rich plasma in the supernatant is separated from the erythrocytes and leukocytes by centrifugation at 700 ⁇ g for 20 minutes at room temperature. The platelets are lysed by ultrasound and used in the PDE 3 assay.
• the phosphodiesterase activity is modified with some modifications according to the method described by Thompson et al. described method determined. (Thompson, WJ; Appleman, MM, Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme. Adv. Cycl. Nucl. Res. 1979, 10, 69-92).
• the reaction mixtures contain 50 mM Tris-HCl (pH 7.4), 5 mM MgCl2, the inhibitors in variable concentrations, the enzyme preparation and the other components necessary for the detection of the individual isoenzyme PDE 3 (see below).
• the reaction is started by adding the substrate 0.5 ⁇ M [ 3 H] -cAMP (approx. 6000 CPM / test). The final volume is 100 ml.
• Test substances are prepared as stock solutions in DMSO.
• the DMSO concentration in the reaction mixture is 1% v / v. At this DMSO concentration, the PDE 3 activity is not affected.
• the samples are incubated at 37 ° C. for 30 minutes.
• the reaction is stopped by heating the test tubes to 110 ° C.
• IC 50 values in the range from 10 "9 to 10 " 5 M were determined for the compounds according to the invention. For example, the following values were determined for selected exemplary embodiments:
• PDE 5 activity is determined in enzyme preparations from human platelets. Human blood was anticoagulated with citrate. The platelet-rich plasma in the supernatant is separated from the erythrocytes and leukocytes by centrifugation at 700 xg for 20 minutes at room temperature. The platelets are lysed by ultrasound and used in the PDE 5 assay.
• the phosphodiesterase activity is determined with some modifications according to the method described by Thompson et al (Thompson, WJ, Appleman, MM, Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme Adv Cycl Nucl Res 1979, 10, 69- 92)
• the reaction mixtures contain 50 mM T ⁇ s-HCl (pH 7.4), 5 mM MgCl2, the inhibitors in variable concentrations, the enzyme preparation and the other components necessary for the detection of the individual isoenzyme PDE 5 (see below) by adding the substrate 0.5 ⁇ M [ 3 H] -cGMP (approx. 6000 CPM / test) the reaction is started.
• the final volume is 100 ml of test substances are prepared as stock solutions in DMSO. Concentration in the reaction mixture is 1% v / v. At this DMSO concentration, the PDE 5 activity is not affected.
• the samples are incubated at 37 ° C. for 30 minutes. The reaction is stopped by heating the test tubes to 110 ° C. for 2 minutes. The samples remain in the ice for another 10 minutes. After the addition of 30 ⁇ l of 5 ' nucleotidase (1 mg / ml, from a snake venom suspension from Crotalus adamanteus), incubation is carried out at 37 ° C. for 10 minutes.
• the samples are stopped on ice, 400 ⁇ l of a mixture of Dowex-water-ethanol (1 + 1 + 1) are added, mixed well and incubated again on ice for 15 minutes.
• the reaction tubes are centrifuged at 3000 xg for 20 minutes. 200 ⁇ l aliquots of the supernatant are transferred directly to scintillation vials. After adding 3 ml of scintillator, the samples are measured in the beta counter.
• the non-specific enzyme activities are determined in the presence of 100 ⁇ M IBMX when determining the PDE 5 and subtracted from the test values.
• 5 IC 50 values in the range from 10 "9 to 10 " 5 M were determined with regard to the inhibition of the phosphodiesterase. For example, the following values were determined for selected exemplary embodiments.
• Rat fetal lung fibroblast cells RFL-6 represent a suitable medium to investigate the influence of NO on intracellular cGMP levels (Ishii et al. 1991).
• the basic mechanism is transferable to the smooth vascular muscles.
• the compounds according to the invention amplify the increase in the intracellular cGMP levels induced by the NO donor S-nitroso-N-acetyl-D, L-penicillamine.
• Compound 1 for example, significantly induces an increase in the cGMP level at a concentration of 0.010 ⁇ mol / l.
• the effectiveness of compound 1 is 10,000 times stronger than that obtained by using the non-specific PDE inhibitor 3-isobutyl-1-methylxanthine (IBMX) is reached
• the A brachiahs were then prepared to record the peripheral blood pressure.
• a micro-tip catheter was inserted over the right a carotis for the registration of the systolic / diastolic left ventricular pressure.
• the cardiac output was determined by thermodilution.
• a Swan-Ganz catheter was used for this V femora s inserted The catheter was positioned so that the tip of the blood pressure in the pulmonary artery could be measured. 3.0 ml of physiological saline solution (temperature 4.0 ° C) was injected and the cardiac output from the change in the temperature in the aortic stem certainly
• the surface ECG was derived from the limbs.
• the EKG parameters were evaluated automatically. All blood pressure values were recorded and calculated using a computer-based system

Landscapes

• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Endocrinology (AREA)
• Reproductive Health (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Hospice & Palliative Care (AREA)
• Gynecology & Obstetrics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Applications Claiming Priority (5)

Publications (1)

Family

ID=26051406

Family Applications (1)

Country Status (23)

Families Citing this family (17)

Family Cites Families (2)

• 2000
  • 2000-01-14 AU AU22912/00A patent/AU2291200A/en not_active Abandoned
  • 2000-01-14 BR BR0007613-9A patent/BR0007613A/pt not_active Application Discontinuation
  • 2000-01-14 EE EEP200100377A patent/EE200100377A/xx unknown
  • 2000-01-14 WO PCT/EP2000/000260 patent/WO2000043392A2/de not_active Application Discontinuation
  • 2000-01-14 IL IL14415600A patent/IL144156A0/xx unknown
  • 2000-01-14 JP JP2000594808A patent/JP2002535330A/ja active Pending
  • 2000-01-14 HU HU0105132A patent/HUP0105132A3/hu unknown
  • 2000-01-14 CZ CZ20012627A patent/CZ20012627A3/cs unknown
  • 2000-01-14 TR TR2001/02121T patent/TR200102121T2/xx unknown
  • 2000-01-14 KR KR1020017009112A patent/KR20010101603A/ko not_active Application Discontinuation
  • 2000-01-14 EA EA200100792A patent/EA200100792A1/ru unknown
  • 2000-01-14 ID IDW00200101592A patent/ID29790A/id unknown
  • 2000-01-14 EP EP00901561A patent/EP1144410A2/de not_active Withdrawn
  • 2000-01-14 CN CN00805307A patent/CN1344268A/zh active Pending
  • 2000-01-14 SK SK1032-2001A patent/SK10322001A3/sk unknown
  • 2000-01-19 CA CA002296224A patent/CA2296224A1/en not_active Abandoned
  • 2000-01-19 CO CO00002747A patent/CO5190700A1/es not_active Application Discontinuation
  • 2000-01-19 AR ARP000100246A patent/AR022318A1/es unknown
• 2001
  • 2001-06-29 IS IS5987A patent/IS5987A/is unknown
  • 2001-07-05 NO NO20013334A patent/NO20013334L/no not_active Application Discontinuation
  • 2001-07-17 BG BG105714A patent/BG105714A/xx unknown
  • 2001-07-19 LT LT2001078A patent/LT2001078A/xx not_active Application Discontinuation
  • 2001-07-19 LV LV010109A patent/LV12793B/lv unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events